INmune Bio (NASDAQ:INMB) Earns Buy Rating from Analysts at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of INmune Bio (NASDAQ:INMB) in a research report report published on Tuesday morning, Marketbeat.com reports. The firm issued a buy rating and a $23.00 price objective on the stock.

Separately, Alliance Global Partners began coverage on shares of INmune Bio in a research report on Monday, October 21st. They set a “buy” rating and a $20.00 price objective on the stock. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, INmune Bio has an average rating of “Buy” and an average price target of $20.75.

INmune Bio Price Performance

Shares of INMB opened at $9.22 on Tuesday. The firm has a fifty day moving average price of $5.62 and a 200 day moving average price of $6.08. The stock has a market cap of $204.43 million, a PE ratio of -4.23 and a beta of 1.78. INmune Bio has a 1-year low of $4.32 and a 1-year high of $14.74.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.11). During the same period in the prior year, the business earned ($0.48) earnings per share. As a group, equities analysts expect that INmune Bio will post -2.24 EPS for the current fiscal year.

Hedge Funds Weigh In On INmune Bio

Several institutional investors have recently bought and sold shares of the company. Praetorian PR LLC increased its stake in shares of INmune Bio by 61.0% during the third quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock worth $4,209,000 after acquiring an additional 295,800 shares during the period. Marshall Wace LLP increased its position in INmune Bio by 332.1% during the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after purchasing an additional 89,091 shares during the period. State Street Corp raised its stake in shares of INmune Bio by 35.1% during the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after buying an additional 58,838 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of INmune Bio during the 3rd quarter worth approximately $249,000. Finally, Westside Investment Management Inc. lifted its holdings in shares of INmune Bio by 57.3% in the 3rd quarter. Westside Investment Management Inc. now owns 71,315 shares of the company’s stock valued at $384,000 after buying an additional 25,975 shares during the period. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.